Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 262-104-4 | CAS number: 60207-90-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
- Skin sensitisation: sensitising, male/female, Guinea pig, OECD TG 406, Sommer 1999
- Respiratory sensitisation: not expected to be of concern for respiratory sensitisation
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2 Aug 1999 to 26 Aug 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Version / remarks:
- July 17, 1992
- Qualifier:
- according to guideline
- Guideline:
- other: 96/54/EC, IV.C
- Version / remarks:
- July 30, 1996
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Currently no LLNA study is available for assessment. The GPMT test has been carried out as an animal test to predict human sensitization for over a decade and is recommended by international test guidelines such as OECD.
- Species:
- guinea pig
- Strain:
- other: Himalayan Spotted [GOHI Ibm: GOHI (SPF)]
- Sex:
- male/female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Females nulliparous and non-pregnant: Yes
- Age/weight at dosing: Approximately 1-2 months / 320-431 g
- Housing: Individually in Macrolon Type 3 cages
- Acclimatisation period: At least 5 days
- Diet: Ad libitum
- Water: Municipal water supply ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature: 22 ± 3°C
- Humidity: 50 ± 20%
- Air changes: Approximately 13 - 14 per hour
- Photoperiod: 12 hours light / 12 hours dark
IN-LIFE DATES: 2 Aug 1999 to 26 Aug 1999 - Route:
- intradermal
- Vehicle:
- physiological saline
- Concentration / amount:
- Injection: 0.1 mL
Treatment: adjuvant/physiological saline mixture, 1:1 (v/v)
Control: adjuvant/physiological saline mixture, 1:1 (v/v) - Day(s)/duration:
- Day 0: First injection out of the three pairs of intradermal injections
- Route:
- intradermal
- Vehicle:
- other: peanut oil
- Concentration / amount:
- Injection: 0.1 mL
Treatment: 5% in peanut oil
Control: peanut oil - Day(s)/duration:
- Day 0: Second injection out of the three pairs of intradermal injections
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- Route:
- intradermal
- Vehicle:
- other: peanut oil
- Concentration / amount:
- Injection: 0.1 mL
Treatment: 5% test substance in adjuvant/physiological saline mixture, 1:1 (v/v)
Control: peanut oil, 50% (w/v) with adjuvant/physiological saline mixture, 1:1 (v/v) - Day(s)/duration:
- Day 0: Third injection out of the three pairs of intradermal injections
- Adequacy of induction:
- highest concentration used causing mild-to-moderate skin irritation and well-tolerated systemically
- Route:
- epicutaneous, occlusive
- Vehicle:
- unchanged (no vehicle)
- Concentration / amount:
- Patch: 2x4 cm; approx. 0.4 g per patch; occlusive dressing
Treatment: 100% test substance
Control: vaseline - Day(s)/duration:
- Day 8: Occlusive dressing for 48 hours
- Adequacy of induction:
- highest technically applicable concentration used
- No.:
- #1
- Route:
- epicutaneous, occlusive
- Vehicle:
- petrolatum
- Concentration / amount:
- Concentration: 30% test substance (both control as treatment group)
Amount: 0.35 mL
Two treatments were placed on all animals: test substance on the test flank and vehicle on the vehicle flan - Day(s)/duration:
- Day 21: occlusive dressing for 48 hours
- Adequacy of challenge:
- highest non-irritant concentration
- No. of animals per dose:
- 10 animals in the vehicle control group and 20 animals in the test group
- Details on study design:
- RANGE FINDING TESTS:
Intravenous Inderuction Pretest
- Concentrations of test item and vehicle: 0.5, 1.0, 3.0 and 5.0% in peanut oil
- Pre-treatment: A 5-cm wide area in the neck-shoulder region of 1 male and 1 female animal was shaved approximately 1 hour before treatment.
- Treatment: One pair of intradermal injections (0.1 mL) of a 1:1 mixture of FCA/physiological saline and one pair of injections for each concentration were administered, one of each pair on each side of the spine.
- Observations: The test sites were examined 24 and 48 hours after administration to determine the highest concentration to produce mild to moderate irritation without systemic toxicity.
Epidermal Induction Pretest
- Concentrations of test item and vehicle: 30, 50 and 80% in vaseline and 100% (undiluted).
- Pretreatment: Two pairs of intradermal injections (0.1 mL) of a 1:1 mixture of FCA/physiological saline were administered to 1 male and 1 female animal.
- Treatment: Seven days later, the test item/vehicle mixtures and the undiluted test item were applied with four Hill Top Chambers, two on each flank of both animals.
- Observations: The test sites were examined 24 and 48 hours after administration to determine the highest concentration to cause mild to moderate irritation for the induction application and no irritation for the challenge application (highest non-irritant dose).
MAIN STUDY:
Treatment schedule: A set of intradermal induction injections was made on Day 0. An epidermal induction application was made once on Day 8. The epidermal challenge application was made once on Day 21.
A. INDUCTION EXPOSURE
- Intradermal Induction Injections: Concentration of test item and vehicle: 5.0% in peanut oil.
- Pretreatment: An area approximately 5 cm x 5 cm on the back of the neck was shaved approximately 1 hour before treatment.
Treatment (Day 0): Three pairs of injections (0.1 mL in volume) were applied into the shaved area by making sure that one of each pair was on each side of the midline.
- Vehicle control group injections:
(1) adjuvant/physiological saline mixture, 1:1 (v/v)
(2) peanut oil
(3) peanut oil, 50% (w/v) with 1:1 adjuvant/physiological saline mixture
- Test item group injections:
(1) adjuvant/physiological saline mixture, 1:1 (v/v)
(2) test substance in peanut oil
(3) test substance in 1:1 adjuvant/physiological saline mixture
Treatment (Day 8): Epidermal Application Induction
- Concentration of test item: 100% (undiluted test item)
- Treatment: A filter paper patch was fully loaded (approximately 0.4 g) with the test Item (test item group) or vaseline vehicle alone (vehicle control group) and held in place with the occlusive dressing for 48 hours.
B. CHALLENGE EXPOSURE
- Epidermal Application Challenge (Day 21)
- Vehicle: Vaseline
- Concentration tested, test item: 30% (highest non-irritant dose)
- Pretreatment: The flanks of all animals were shaved immediately prior to treatment.
Treatment (Day 21): One chamber loaded with the test item/vehicle mixture (approximately 0.35 mL) was placed on one flank (test flank) and one chamber loaded with the vehicle alone was placed on the other flank (vehicle flank) of the animals of both groups. The chambers were held in place with the occlusive dressing for 24 hours.
- Period of observation: Through 48 hours after completion of the challenge application.
- Skin irritation check: Application sites were examined 1 hour after removal of the epidermal induction dressing on Day 10 and rated for positive or negative skin irritation reactions.
- Scoring intervals: 24 and 48 hours after removal of the dressing for the challenge application.
- Grading of skin reactions: Dermal reactions were graded according to the Draize scale
OTHER:
- Method of sacrifice: CO2 asphyxiation
- Clinical observations: Checked daily; any remarkable findings, with indication of severity, were recorded.
- Mortality: Checked daily
- Body weight: Measured and recorded immediately before treatment and at study termination.
- Grading of skin reactions: Please, see 'Any other information on materials and methods incl. tables' section - Challenge controls:
- Vehicle without test substance
- Positive control substance(s):
- yes
- Remarks:
- Benzocaine 30%, checked periodically
- Positive control results:
- Latest Reliability Check: Very slight or well defined erythema was seen in 12/20 test animals, 24 hours after challenge, and in 10/20 test animals 48 hours after challenge. There was no erythema seen in any of the controls. The net response was, therefore, 60% and benzocaine was classified as a moderate skin sensitiser and confirmed the sensitivity of the test system.
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 30%
- No. with + reactions:
- 6
- Total no. in group:
- 20
- Clinical observations:
- no clinical signs observed
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 30%
- No. with + reactions:
- 10
- Total no. in group:
- 20
- Clinical observations:
- no clinical signs observed
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 30% vaseline
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no clinical signs observed
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 30% vaseline
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- no clinical signs observed
- Remarks on result:
- no indication of skin sensitisation
- Key result
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 30 % benzocaine
- No. with + reactions:
- 12
- Total no. in group:
- 20
- Clinical observations:
- Very slight or well defined erythema
- Remarks on result:
- positive indication of skin sensitisation
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 30 % benzocaine
- No. with + reactions:
- 10
- Total no. in group:
- 20
- Clinical observations:
- Very slight or well defined erythema
- Remarks on result:
- positive indication of skin sensitisation
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- In a dermal sensitisation study performed in compliance with GLP and following the OECD 406 guideline, positive skin reactions on the test flanks were observed in 2 males and 4 females of the test group animals at the 24-hour examination and in 5 males and 5 females at the 48-hour examination; the sensitisation rate for the test substance was therefore 50%. Desquamation was seen in 3 males and 3 females at the 48-hour observation. Therefore, the test substance is considered to be a skin sensitiser.
- Executive summary:
In a dermal sensitisation study performed in compliance with GLP and following the OECD 406 guideline, young adult, male and female, Himalayan Spotted (GOHI Ibm:GOHI (SPF) guinea pigs (10/sex test group, 5/sex vehicle controls) were tested with the test substance using the method of Magnusson and Kligman. For the main study, the concentrations used were: intradermal injections 5.0% test substance in peanut oil; epidermal induction application undiluted test substance; epidermal challenge applications 30% test substance in Vaseline and vehicle alone. From the findings of a pilot study, 30% test substance concentration was the highest concentration that caused no skin irritation.
A positive control experiment with benzocaine was performed and confirmed the sensitivity of the test system. Positive skin reactions on the test flanks were observed in 2 males and 4 females of the test group animals at the 24-hour examination and in 5 males and 5 females at the 48-hour examination; the sensitisation rate for the test substance was therefore 50%. Desquamation was seen in 3 males and 3 females at the 48-hour observation. There were no allergic skin reactions on the vehicle flanks and in the vehicle control group. There was no mortality, and there were no remarkable clinical observations in either group. Body weights were not affected by treatment. Therefore, the test substance is considered to be a skin sensitiser.
Reference
Table 1. Magnusson and Kligman test: Number of animals with positive signs of allergic skin reactions following challenge
|
Challenge with 30% test substance |
Challenge with Vaseline |
||
Scored after: |
24 hours |
48 hours |
24 hours |
48 hours |
Main test – test group |
6/20 |
10/20 |
0/20 |
0/20 |
Main test – negative vehicle control |
0/10 |
0/10 |
0/10 |
0/10 |
|
Challenge with 30% benzocaine |
|||
|
24 hours |
48 hours |
||
Positive control – test group |
12/20 |
10/20 |
||
Positive control – vehicle control |
0/10 |
0/10 |
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
All available data was assessed and the studies representing the worst-case effects were included as key studies. All other information was included as supporting information. The in vitro data requirements were waived based on the availability of adequate in vivo data. The test substance is considered to be a skin sensitiser based on the results of the key study.
Skin Sensitisation
In the key study (Sommer 1999), performed in compliance with GLP and following the OECD TG 406, young adult, male and female, Himalayan Spotted (GOHI Ibm:GOHI (SPF) guinea pigs (10/sex test group, 5/sex vehicle controls) were tested with the test substance using the method of Magnusson and Kligman. For the main study, the concentrations used were: intradermal injections 5.0% test substance in peanut oil; epidermal induction application undiluted test substance; epidermal challenge applications 30% test substance in Vaseline and vehicle alone. From the findings of a pilot study, 30% test substance concentration was the highest concentration that caused no skin irritation.
A positive control experiment with benzocaine was performed and confirmed the sensitivity of the test system. Positive skin reactions on the test flanks were observed in 2 males and 4 females of the test group animals at the 24-hour examination and in 5 males and 5 females at the 48-hour examination; the sensitisation rate for the test substance was therefore 50%. Desquamation was seen in 3 males and 3 females at the 48-hour observation. There were no allergic skin reactions on the vehicle flanks and in the vehicle control group. There was no mortality, and there were no remarkable clinical observations in either group. Body weights were not affected by treatment. Therefore, the test substance is considered to be a skin sensitiser.
A supporting study (Ullmann 1978) is available. The study was performed according to an AFDO (1959) guideline and was not GLP compliant. The test substance was administered to male and female guinea pigs as an intradermal injection and epicutaneous application at a dose of 0.1 mL 0.1 % dilution in the vehicle. No differences between the test group and the vehicle-treated controls were seen, after either intradermal or epidermal challenge application of the test substance. The test substance was found to be devoid of skin sensitising (contact allergenic) potential in albino guinea pigs.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
The test substance is not expected to be of concern for respiratory sensitisation. Following the recommended approach outlined in R.7.3.12.3, the test substance is not expected to be a respiratory sensitiser because the test substance is not di-isocyanate or protein. Furthermore, no structural warnings for respiratory sensitisation were found using the QSAR toolbox (v4.4).
Justification for classification or non-classification
Based on the available information, the test substance is classified as a skin sensitiser category 1, H317: May cause an allergic skin reaction in accordance with EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.